# DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

> **NCT05701917** · NA · RECRUITING · sponsor: **Inari Medical** · enrollment: 300 (estimated)

## Conditions studied

- Venous Thromboembolism
- Deep Venous Thrombosis
- Post-Thrombotic Syndrome

## Interventions

- **DEVICE:** ClotTriever System
- **DRUG:** Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

## Key facts

- **NCT ID:** NCT05701917
- **Lead sponsor:** Inari Medical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-06
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-01-15
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701917, "DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05701917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*